FTMAP: Extended Protein Mapping with User-selected Probe Molecules
News May 23, 2012
Binding hot spots, protein sites with high-binding affinity, can be identified using X-ray crystallography or NMR by screening libraries of small organic molecules that tend to cluster at such regions. FTMAP, a direct computational analog of the experimental screening approaches, globally samples the surface of a target protein using small organic molecules as probes, finds favorable positions, clusters the conformations and ranks the clusters on the basis of the average energy. The regions that bind several probe clusters predict the binding hot spots, in good agreement with experimental results. Small molecules discovered by fragment-based approaches to drug design also bind at the hot spot regions. To identify such molecules and their most likely bound positions, we extend the functionality of FTMAP (http://ftmap.bu.edu/param) to accept any small molecule as an additional probe. In its updated form, FTMAP identifies the hot spots based on a standard set of probes, and for each additional probe shows representative structures of nearby low energy clusters. This approach helps to predict bound poses of the user-selected molecules, detects if a compound is not likely to bind in the hot spot region, and provides input for the design of larger ligands.
This article is published online in Nucleic Acids Research and is free to access.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Researchers Identify Druggable Genomic Targets in Malaria ParasiteNews
Using whole-genome analysis and chemogenomics, scientists have discovered novel antimalarial drug targets and drug-resistance genes. The researchers analyzed >250 Plasmodium falciparum cell lines, which were resistant to 37 different anti-malarial compounds.READ MORE
Vanderbilt and Lundbeck to Develop a Novel Approach for Treating SchizophreniaNews
Vanderbilt University has signed separate licensing and research collaboration agreements with Lundbeck, to develop a novel approach for treating schizophrenia. The Vanderbilt compounds have been shown in animal models to have antipsychotic-like effects and to improve cognitive performance with low risk of side effects.READ MORE